š° Full Story
A U.S. trade tribunal on April 17, 2026, declined to review an administrative judgeās March finding that Appleās redesigned blood-oxygen feature for the Apple Watch does not infringe Masimo patents, effectively closing the case and blocking Masimoās bid to reinstate an import ban.
The International Trade Commissionās decision follows Appleās August relaunch of a modified implementation ā which shifts display of blood-oxygen readings to associated iPhones rather than the watch ā after Customs and Border Protection cleared the updated devices.
The dispute dates back to a 2023 ITC ruling that briefly halted imports of Appleās Series 9 and Ultra 2 models; Apple removed the feature at the time to keep products flowing.
Masimo, owned by Danaher, can appeal the ITC closure to the U.S. Court of Appeals for the Federal Circuit and has separately pursued litigation against U.S. Customs and in California federal court, where it won a $634 million patent verdict in November.
Apple praised the ruling as protecting its health feature and signalled continued defence of its innovations.
The outcome removes an immediate import threat for Appleās wearables in the U.S. but leaves broader legal disputes unresolved.






š¬ Commentary